# An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

> **NCT00407095** · PHASE3 · COMPLETED · sponsor: **Solvay Pharmaceuticals** · enrollment: 140 (estimated)

## Conditions studied

- Advanced Stage Parkinson's Disease

## Interventions

- **DRUG:** Pardoprunox

## Key facts

- **NCT ID:** NCT00407095
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2010-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00407095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00407095, "An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00407095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*